Genelux Corp (GNLX)
Health Care · Biotechnology · NASDAQ
Genelux is a clinical-stage biotechnology company developing off-the-shelf, oncolytic vaccinia virus therapies designed to re-sensitize resistant solid tumors to conventional treatments.
What Genelux Corp does
Genelux is a late clinical-stage biopharmaceutical company focused on developing oncolytic viral immunotherapies for aggressive and difficult-to-treat solid tumors. The company's lead product candidate, Olvi-Vec, is a proprietary, modified vaccinia virus designed to selectively kill tumor cells and trigger a patient-specific immune response. Genelux operates its own cGMP manufacturing facility and utilizes a proprietary discovery platform (CHOICE) to engineer its therapeutic pipeline.
Recent developments
In June 2026, the company published translational and clinical findings from its Phase 1b/2 VIRO-15 trial regarding the impact of Olvi-Vec-primed immunochemotherapy in platinum-resistant/refractory ovarian cancer. In the second quarter of 2026, the company raised approximately $0.3 million through its at-the-market (ATM) offering program.
From Genelux Corp's filing of 2026-08-13.
Themes: Oncology / Immunotherapy, Oncolytic viruses, Solid tumors, Ovarian cancer, Lung cancer, Drug manufacturing
Fundamentals
- Price$2.50 as of 2026-10-20 close
- Market cap$113M as of 2026-08-11 (share count; price 2026-10-20)
- 1-year return-61.6% 2025-10-20 close $6.51 → 2026-10-20 close $2.50
- P/En/a negative earnings
- Net margin-401812.5% FY2025, SEC XBRL
- ROE-278.5% FY2025, SEC XBRL
- ROICn/a No figure: its 10-K tags no pre-tax income, so no tax rate can be taken.
- Debt / equityn/a No figure: its filing tags none of the debt lines we read, which is not evidence of zero debt.
- Revenue CAGR (3y)-91.0% SEC XBRL
- Beta1.40 as of 2026-09-03
- Last reported earnings2025-03-25 most recent in our data — SEC EDGAR Form 8-K (Item 2.02); no newer announcement filed
How GNLX compares in its sector
- net profit marginbottom 10% 430 covered Health Care peers, as of 2026-09-03
- operating marginbottom 10% 417 covered Health Care peers, as of 2026-09-03
- return on equitybottom 10% 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRbottom 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Quarterly results
| Quarter | Operating income | Net income | Diluted EPS | Operating cash flow | Capex |
|---|---|---|---|---|---|
| Q2 FY2026 2026-06-30 | -$10M | -$9M | -$0.21 | -$6M† | $2M† |
| Q1 FY2026 2026-03-31 | -$9M | -$9M | -$0.20 | -$6M | $921000 |
| Q4 FY2025 2025-12-31 | -$9M† | -$9M† | -$0.24† | -$6M† | $436000† |
| Q3 FY2025 2025-09-30 | -$8M | -$8M | -$0.21 | -$7M† | $517000† |
| Q2 FY2025 2025-06-30 | -$8M | -$7M | -$0.20 | -$7M† | $115000† |
| Q1 FY2025 2025-03-31 | -$8M | -$7M | -$0.21 | -$5M | $30000 |
| Q4 FY2024 2024-12-31 | -$10M† | -$9M† | -$0.26† | -$4M† | $96000† |
| Q3 FY2024 2024-09-30 | -$7M | -$6M | -$0.19 | -$6M† | $27000† |
† Not filed as a discrete quarter: derived from the company's own year-to-date figures (for example the fourth quarter as the fiscal year minus the first nine months). A derived per-share figure is approximate, because the share count moves within the year.
Balance sheet at 2026-06-30
- Cash and equivalents$9M
- Short-term investments$10M
- Total debtnot shown the filing tags none of the debt lines we read — not evidence of zero debt
From the company's own SEC 10-Q and 10-K filings (XBRL), re-read every week. Figures in US dollars as filed; informational only — not financial advice.
How Genelux Corp looks technically
Genelux Corp (GNLX) is trading 9.2% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 177 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 12, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 49, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 5 trading days ago (its momentum flipped negative). It made a new 20-day low about 5 trading days ago. It is 70.7% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 9.2% below its 200-day average, the long-term trend line — a long-term downtrend | -9.2% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $2.56 | $2.56 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $2.75 | $2.75 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 15 calendar days ago — the swings before that are what the structure reading is measured on | 15 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes above 2.66. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible downward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 177 trading days ago — a "death cross", a bearish long-term signal | 177 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 12, below the 25 that marks a real trend) | 12.3 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 49, neither overbought (above 70) nor oversold (below 30) | 49.2 |
|---|---|---|
| Position in its 14-day range | it is trading around the middle of its 14-day range ($2.32 to $2.66) — its "stochastic" reading is 53 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 52.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 5 trading days ago (its momentum flipped negative) | 5 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $8.54 | $8.54 |
|---|---|---|
| From the 52-week high | it is 70.7% below its 52-week high (its highest price of the past year) | -70.7% |
| Above the 52-week low | it is 9.2% above its 52-week low (its lowest price of the past year) | +9.2% |
| Below the 52-week high | it is 70.7% below its highest point of the past year | 70.7% |
| Since a 20-day breakout | it made a new 20-day low about 5 trading days ago | 5 sessions |
| Since a 55-day breakout | it made a new 55-day low about 5 trading days ago | 5 sessions |
| All-time high | its highest closing price on record is $40.98 (set on 2023-06-22) | $40.98 |
| Given back of the 52-week move | over the past year its closes ranged ($2.30 to $8.24), and it has recovered only a small part of its fall from last year’s high — 3% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $5.97 to $6.16. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 3.4% |
| From the all-time high | it is 93.9% below its all-time high | -93.9% |
| Nearest price level | it is trading 6.3% below a resistance level at $2.66 — a price it turned at three times since 2026-06-17, most recently on 2026-10-05. Since 2024-10-21 it has 2 such levels below the current price and 13 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +6.3% |
| All-time low | its lowest closing price on record is $1.60 (set on 2024-08-05) | $1.60 |
| Above the all-time low | it is 56.2% above its all-time low | +56.3% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 34th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.1335 between its high and its low — about 5.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.1335 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $2.37 and $2.62 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $2.37 – $2.50 – $2.62 |
| Typical daily range (% of price) | its price moves about 5.3% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.3% |
| Stretch from the 200-day average | it is trading 1.9 daily ranges below its 200-day average price (9.2% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.9 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.28× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
1
| Since a doji | 9 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 9 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-10-20 0.8% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.8% |
|---|---|---|
| Open gap | it gapped 3.5% above the previous close 3 sessions ago and has not traded back through the level it left behind at 2.32 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +3.5% |
| Gap filled | a 2.8% gap up opened on 2026-09-15 has been "filled" 25 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 25 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +3.31% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 2.2 percentage points (the stock lost 1.2% while the market gained 1.0%) | -2.1% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 18.3 percentage points (the stock lost 14.7% while the market gained 3.6%) | -18.3% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 14.2 percentage points (the stock lost 5.7% while the market gained 8.5%) | -14.2% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 76.2 percentage points (the stock lost 61.6% while the market gained 14.6%) | -76.2% |
Signal agreement
2
| Bullish technical signals | 0 of the 9 technical signals we can compute for it are currently in a bullish state — these describe past price behaviour, not a forecast | 0 of 9 |
|---|---|---|
| Bearish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, MACD momentum is negative, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 4.4% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-14 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 6.8% of the share price. | -4.4% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 8% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $2.72 — a volume-weighted average of daily closes over 198 sessions, not a true tick-by-tick VWAP. | -8.0% |
|---|---|---|
| Vs the average paid since it last reported | the price is 3% below the average price paid since it last reported on 2026-08-13 (its 10-Q), so the typical buyer over that stretch is under water. That average is $2.57 — a volume-weighted average of daily closes over 48 sessions, not a true tick-by-tick VWAP. | -2.6% |
Price levels it has turned at before
GNLX last closed at $2.50 on 2026-10-20. Since 2024-10-21 it has turned at 2 prices below its last close and 13 above; the 2 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $2.66 | Resistance | 6.3% above the last close | turned there three times · 2026-06-17 to 2026-10-05 |
| $2.31 | Support | 7.5% below the last close | turned there 7 times · 2024-11-15 to 2026-09-16 |
| $2.25 | Support | 9.9% below the last close | turned there twice · 2025-01-15 to 2025-05-07 |
| $2.76 | Resistance | 10.3% above the last close | turned there six times · 2025-01-07 to 2026-09-10 |
| $2.81 | Resistance | 12.3% above the last close | turned there three times · 2025-05-21 to 2026-08-14 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes above $2.66.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $1.98 and $2.24 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close above $2.66.
This reading has stood for 15 trading days, since 2026-09-30.
Read from daily closes as of 2026-10-20.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Trading below the 50-day moving average · Pulled back from the 12-month high · MACD just crossed bearish (12/26/9) · trendless / choppy (low ADX) · lagging the market | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-20. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$18.83 range $12.00 – $31.00; median $17.00
Analyst estimates, as of 2026-10-16. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for GNLX
- Consensus EPS estimate-$0.1983 next reporting period, as of 2026-10-16
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Significant operating losses and reliance on future capital raises to sustain operations.","Risks associated with clinical trial outcomes and regulatory approval processes for unproven, novel therapeutic candidates.","Potential impact of international trade policies, tariffs, and supply chain disruptions on research, development, and manufacturing costs."]
What changed in the latest 10-Q
AI-assisted comparison of GNLX's 10-Q filed 2026-08-13 against the prior one filed 2026-05-07.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-08-13) reports net losses of $18.4 million and $14.9 million for the six months ended June 30, 2026 and 2025, respectively.
- Newer filing (2026-08-13) reports accumulated deficit of $301.9 million as of June 30, 2026.
- Newer filing (2026-08-13) adds disclosure that the company sold 120,087 shares of common stock to an existing stockholder under the ATM Agreement with TD Securities (USA) LLC in the second quarter of 2026, with net proceeds of $0.3 million.
- Newer filing (2026-08-13) adds disclosure that financing may include sales under the ATM Agreement.
- Newer filing (2026-08-13) adds 'Recent Developments - Publication' subsection describing a June 2026 announcement of publication of translational and clinical findings from the Phase 1b/2 VIRO-15 trial in Gynecologic Oncology Reports.
- Newer filing (2026-08-13) adds 'Recent Developments - ATM Sales' subsection describing second quarter 2026 ATM sales of 120,087 shares for net proceeds of $0.3 million.
- Newer filing (2026-08-13) reports stockholders' equity of $16.1 million at June 30, 2026.
- Newer filing (2026-08-13) reports cash, cash equivalents, restricted cash and marketable securities totaling $18.7 million at June 30, 2026.
- Removed:
- Older filing (2026-05-07) reports net losses of $8.9 million and $7.5 million for the three months ended March 31, 2026 and 2025, respectively.
- Older filing (2026-05-07) reports accumulated deficit of $292.5 million as of March 31, 2026.
- Older filing (2026-05-07) includes 'Recent Developments - Data from Lung Cancer Clinical Trials' subsection describing January 5, 2026 interim results from SCLC and NSCLC trials evaluating systemic Olvi-Vec.
- Older filing (2026-05-07) reports stockholders' equity of $22.9 million at March 31, 2026.
- Older filing (2026-05-07) reports cash, cash equivalents, restricted cash and marketable securities totaling $26.3 million at March 31, 2026.
- Reworded:
- Newer filing (2026-08-13) changes the funding sources description to include 'which may include sales under the ATM Agreement' in the sentence about financing operations, whereas the older filing (2026-05-07) did not include this phrase.
- Newer filing (2026-08-13) changes the period referenced for net losses and accumulated deficit from three months ended March 31 to six months ended June 30.
- Newer filing (2026-08-13) replaces the 'Data from Lung Cancer Clinical Trials' recent development with 'Publication' and 'ATM Sales' recent developments.
- Notes:
- The newer filing text provided is truncated and ends mid-sentence in the Research and Development Expenses section, so changes after that point cannot be assessed.
- The older filing text provided is also truncated and ends mid-sentence in the Lung Cancer Clinical Trials section, so changes after that point cannot be assessed.
Risk Factors
- Added:
- Newer filing (2026-08-13) added a table under Item 5 Other Information, Trading Arrangements, disclosing that director John Thomas adopted a Rule 10b5-1 trading arrangement on 06/30/2026, with expiration date 12/31/2026, covering up to 8,914 shares.
- Newer filing (2026-08-13) added exhibit 10.1* (Executive Employment Offer Letter, dated November 28, 2025, by and between the Registrant and Jason Litten, M.D.).
- Newer filing (2026-08-13) added exhibit 10.2* (Fourth Amendment to Industrial/Commercial Multi-Tenant Lease, by and between the Registrant and Marindustry Partners, LP, dated March 20, 2026).
- Removed:
- Older filing (2026-05-07) stated that during the three months ended March 31, 2026, no director or officer adopted or terminated any Rule 10b5-1 trading arrangement or any non-Rule 10b5-1 trading arrangement (as such terms are defined pursuant to Item 408(a) of Regulation S-K); this statement was removed in the newer filing (2026-08-13).
- Reworded:
- Older filing (2026-05-07) described the source Annual Report as "(the “Annual Report”)" while newer filing (2026-08-13) described it as "(Annual Report)" (removal of quotation marks and the word 'the').
- Older filing (2026-05-07) contained an asterisk after the risk factor heading "...results of operations and prospects.*"; the newer filing (2026-08-13) does not include this asterisk.
- Older filing (2026-05-07) listed exhibit 4.4 as Form of Warrant incorporated by reference to Exhibit 4.1 to the Registrant's Current Report on Form 8-K filed on May 24, 2024; the newer filing (2026-08-13) text for exhibit 4.4 is truncated and does not show this filing date.
- Notes:
- The newer filing (2026-08-13) exhibit list is truncated after exhibit 4.4, so changes to the exhibits beyond that point could not be fully compared.
- The page numbering differs between filings (newer page 30-31 vs older page 26-27), which reflects layout differences rather than substantive content changes.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 6 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-16. The 5 days since 2026-10-16 have not been checked yet.
- Last 90 days · read to 2026-10-160 buys · 6 sells ($159421) — 3 selling insiders
- Last 180 days · read to 2026-10-160 buys · 13 sells ($237311) — 6 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-31. Based on Form 4 filings read through 2026-10-16; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about GNLX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding GNLX as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 862,544
- Reported value $2,596,258
reported quarterly holdings change (2026-03-31 → 2026-06-30): 1 new, 2 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about GNLX's institutional holders → See what each manager we track holds →
Short interest (FINRA)
GNLX had 4,362,110 shares of reported short interest as of the 2026-09-30 FINRA settlement date (delayed, bi-monthly; not real-time).
GNLX had 9.64% of its shares outstanding sold short as of the 2026-09-30 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 20.43 days to cover at the same settlement.
- Reported short interest (shares) 4,362,110
- Short interest (% of shares outstanding) 9.64%
- Prior settlement (shares) 4,096,285
- Reported change 6.49%
- Days to cover (reported) 20.43
Reported to FINRA as of the 2026-09-30 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare GNLX vs…
Frequently asked questions
What does Genelux Corp (GNLX) do?
Genelux is a late clinical-stage biopharmaceutical company focused on developing oncolytic viral immunotherapies for aggressive and difficult-to-treat solid tumors. The company's lead product candidate, Olvi-Vec, is a proprietary, modified vaccinia virus designed to selectively kill tumor cells and trigger a patient-specific immune response. Genelux operates its own cGMP manufacturing facility and utilizes a proprietary discovery platform (CHOICE) to engineer its therapeutic pipeline.
What sector is Genelux Corp (GNLX) in?
Genelux Corp (GNLX) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are Genelux Corp's (GNLX) competitors?
Notable peers of Genelux Corp (GNLX) include Amgen, Replimune Group, Merck & Co., AstraZeneca and Bristol-Myers Squibb. This peer set is informational only — not financial advice.
Is Genelux Corp (GNLX) overbought or oversold right now?
Genelux Corp (GNLX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 49, in the neutral middle (as of 2026-10-20). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on GNLX come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.